Krystal Biotech (KRYS) Operating Leases (2021 - 2025)
Historic Operating Leases for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $9.5 million.
- Krystal Biotech's Operating Leases rose 2722.04% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 2722.04%. This contributed to the annual value of $6.0 million for FY2024, which is 870.09% down from last year.
- According to the latest figures from Q3 2025, Krystal Biotech's Operating Leases is $9.5 million, which was up 2722.04% from $9.7 million recorded in Q2 2025.
- Krystal Biotech's Operating Leases' 5-year high stood at $9.7 million during Q2 2025, with a 5-year trough of $3.9 million in Q1 2021.
- In the last 5 years, Krystal Biotech's Operating Leases had a median value of $8.3 million in 2023 and averaged $8.1 million.
- In the last 5 years, Krystal Biotech's Operating Leases skyrocketed by 14015.5% in 2022 and then crashed by 2589.28% in 2023.
- Krystal Biotech's Operating Leases (Quarter) stood at $8.0 million in 2021, then grew by 11.33% to $8.9 million in 2022, then decreased by 25.89% to $6.6 million in 2023, then fell by 8.7% to $6.0 million in 2024, then skyrocketed by 57.36% to $9.5 million in 2025.
- Its Operating Leases was $9.5 million in Q3 2025, compared to $9.7 million in Q2 2025 and $9.7 million in Q1 2025.